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Recurrent spontaneous abortion (RSA), defined as the 
occurrence of two or more consecutive miscarriages at less than 
22-weeks of gestation [1], is one of the major pregnancy disorders 
and affects up to 5% of couples of reproductive ages. Although 
genetic factors, hormonal diseases, anatomical anomalies and 
antiphospholipid syndrome have been linked with RSA [2,3], 50% 
of cases still remain unexplained and generate growing interest to 
unveil potential involved mechanisms, particularly for those that 
imply immunological pathways. 
Successful pregnancy requires a highly regulated immune 
balance to achieve embryonic antigen tolerance. The embryo is 
considered a semi-homograft that is not rejected by the maternal 
immune system in a normal pregnancy [4,5]. Any disruption of 
this immune tolerance may have as a consequence pregnancy 
complication including spontaneous abortion. 
The first report proposing an alloimmune mechanism as the 
cause of RSA was published in 1981 and suggested that similarities 
in human leukocyte antigens between father and mother would 
result in the failed production of blocking antibodies, thus 
leading to pregnancy termination [6]. The same year Taylor and 
Faulk published their results from treating three patients with 
unexplained RSA using allogeneic lymphocyte immunotherapy (LIT) 
[7], suggesting that infusion of allogeneic leukocytes stimulated the 
maternal immune system to produce immune tolerance factors that 
prevented spontaneous abortion. 
Almost 40 years after these original reports, despite the 
extensive research in the field of reproductive immunology, 
there is a lack of robust scientific evidence concerning the use 
 
of immune therapies to treat RSA. Furthermore, results from the 
different studies evaluating immune therapies, including paternal 
(or third-party) LIT, but also other approaches like intravenous 
immunoglobulin (IVIG), or administration of trophoblast 
membranes, are contradictory. 
Centers worldwide have been performing LIT as research 
projects, taking the rate of live birth in RSA patients as the main 
output. From these studies, a first meta-analysis published in 1993 
by Fraser et al. evaluated the effect of LIT and did not detect any 
improvement in the rate of live births [8]. Shortly after, in 1994, a 
multicenter study and meta-analysis designed to assess the efficacy 
of LIT concluded that this therapy improved the rate of live births 
in RSA patients with no more than one live birth with any or current 
partner [9]. A significant improvement was observed when the 
patients had antibodies against the lymphocytes of their spouses 
before pregnancy. Similar results were reported by our research 
unit in 2000 [10]. 
A meta-analysis published by Cochrane Library in 2001 
and updated in 2014 assessed different forms of immunologic 
treatment for RSA cases, including LIT, in a total of 641 participants 
(316 treated women and 325 in the placebo group) and showed 
that the treatment effect was not significant [11]. The analysis 
included the results presented by by Ober et al. in 1999, the only 
study published to date observing a negative effect of LIT on the rate 
of live births [12]. This was source of criticisms from researchers 
in the field, mainly because Ober et al. did not exclude patients 
with autoimmune disorders, but also prepared and used paternal 
lymphocytes in conditions that adversely impact in the results of 
American Journal of Biomedical Science & Research
Am J Biomed Sci & Res                                                                                                                                                                 Copy@ Pablo M Fernández
369
LIT [13-15]. 
Recently, Liu et al. published a new meta-analysis including 
numerous clinical trials conducted from 1985 to 2013, and 
demonstrated that LIT promoted a significant improvement in the 
rate of live births (77.8% in treated RSA patients compared to 46.1% 
in the control group), independently of the lymphocytes origin 
(paternal or third-party), and contributing to the understanding of 
the best protocol of immunization [16]. 
The latest works in the field confirm that LIT can be used to 
treat RSA patients to help preventing spontaneous abortion [17,18], 
and explore predictor factors to reach better LIT outcomes [19,20]. 
Overall, current evidence demonstrates that LIT, when performed 
with fresh, non-stored blood, before and during pregnancy, with an 
adequate concentration of lymphocytes, and applied intradermally, 
is a valid and safe treatment for couples with history of RSA of 
unknown cause. 
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